IRTC IRhythm Technologies Inc.

iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

  • iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integration
  • The collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1

SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic’s Aura platform to streamline access to iRhythm’s Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services”) through improved operational efficiency for clinicians.

“Our work with Epic aligns with our goal to optimize clinician workflow efficiencies and provide seamless access to our Zio services. By integrating Zio services into healthcare providers' EHR platforms, we are not just simplifying operations but empowering our health system customers to devote more time to patient care,” said Quentin Blackford, president and chief executive officer of iRhythm. “We believe this integration facilitates improved patient care, ensuring that our customers and their staff can focus on what truly matters—patient health. We are committed to continuous investment in our systems and services to make healthcare more efficient, secure, and patient-focused.”

Through this collaboration, iRhythm and Epic will give healthcare organizations the ability to more efficiently implement Zio services. Through Aura, Epic’s specialty diagnostics and devices suite, we estimate that organizations can save up to 75% of the time it typically takes to integrate Zio services into their local instance of Epic software. iRhythm has already surpassed 1.5 million all-time registrations for Zio services received through EHR-integrated customers. The company estimates this has translated to hundreds of thousands of hours and millions of dollars in staff time costs saved by health systems.

“iRhythm is the first medical device manufacturer to join the Epic community—an addition that reflects the continued growth of the health grid and a more collaborative healthcare ecosystem,” said Alan Hutchison, vice president at Epic. “With longitudinal cardiac data at their fingertips, providers across care settings can more effectively identify and treat the arrhythmias that one-off tests sometimes miss. This kind of technology sets the stage for the eventual proactive monitoring of patients who are at risk for arrhythmias before their symptoms become severe.”

Through this collaboration, iRhythm’s Zio service will be more readily available to healthcare providers using Epic—and the more than 250 million patients in the U.S. who have a record in Epic.

iRhythm is partnering with early adopter customers to integrate Zio services into the Aura network across their health systems in Q4 2024, and the company expects to begin offering this solution to existing and new Zio customers starting in early 2025.

To learn more about how Zio can integrate with your Epic system, please visit . To learn more about iRhythm, please visit .

  1. Zio monitor, XT, and AT are contraindicated for critical care patients

About iRhythm Technologies, Inc.

iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.

Investor Contact

Stephanie Zhadkevich

(919) 452-5430

Media Contact

Saige Smith

(262) 289-7065



EN
29/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

Irhythm Technologies Inc: 1 director

A director at Irhythm Technologies Inc sold 5,000 shares at 175.000USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

 PRESS RELEASE

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial ...

AMALFI Randomized Clinical Trial Results Demonstrate Increased Atrial Fibrillation Diagnosis with Home-Based Long-Term Continuous ECG Monitoring Using iRhythm Technologies’ Zio LTCM Service Oxford University-led AMALFI clinical trial results presented at the European Society of Cardiology (ESC) Congress 2025 and published in the Journal of the American Medical Association (JAMA).AMALFI tested whether home-based, self-applied use of iRhythm’s Zio long-term continuous monitoring (LTCM) device and service could improve diagnosis of atrial fibrillation (AFib) in 5040 participants in the United ...

 PRESS RELEASE

iRhythm Technologies to Participate in Upcoming Investor Conferences

iRhythm Technologies to Participate in Upcoming Investor Conferences SAN FRANCISCO, Aug. 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. Wells Fargo 2025 Healthcare Conference on Wednesday, September 3, 2025, at 12:45 p.m. Eastern Time (9:45 a.m. Pacific Time)Morgan Stanley Global Healthcare Conference 2025 on Tuesday, September 9, 2025, at 2:35 p.m. Eastern Time (11:35 a...

 PRESS RELEASE

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm...

AVALON Real-World Evidence Builds on CAMELOT Study Reinforcing iRhythm’s Zio LTCM Clinical Superiority In the largest real-world study of its kind with 428,707 patients, the Zio LTCM service outperformed other studied monitoring approaches in cardiac arrhythmia diagnostic yield, time to diagnosis, cardiovascular events, and total health care costs.Findings in a younger, commercially insured population build on data from the Medicare fee-for-service, population-based CAMELOT study, confirming the Zio LTCM service’s value across patient populations and payer segments. SAN FRANCISCO, Aug....

 PRESS RELEASE

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution f...

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed to support scalable population health and value-based care strategies SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a digital health leader focused on creating trusted solut...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch